Table 2.
Results from included imatinib studies
| Drug (dose) | Imatinib (600 mg/day) | Imatinib (800 mg/day) | |||
|---|---|---|---|---|---|
| Study | Park et al. [26] | B2222 [23] | Park et al. [26] | S0033 [13] | EORTC-ISG-AGITG [17] |
| Number receiving escalated dose | 12 | 43 | 12 | 118 | 133 |
| Median follow up (range) | 8 months (1.4 to 22.3 months) | 63 months (NR-71 months) | 8 months (1.4 to 22.3 months) | 54 months (NR) | 25 months (NR to 35 months) |
| N (%) with response | NR | NR | NR | 3/117 (2.6%) | 3/133 (2.3%) |
| N (%) with stable disease | NR | NR | NR | 33/117 (28.2%) | 36/133 (27.0%) |
| Total N(%) with response or stable disease | 5/12 (41.7%) | 11/43 (25.6%)b | 4/12 (33.3%) | 36/117 (30.8%) | 39/133 (29.3%) |
| Median overall survival (95% CI)a | NR | NR | NR | 19 months (13 to 23 months) | NR |
| N (%) still alive | NR | NR | NR | 42/118 (35.6%) | NR |
| Progression-free survival (95% CI)a | NR | NR | NR | 5 months (2 to 10 months) | 2.9 months (not reported) |
| N (%) progression free | NR | NR | NR | 19/118 (16.1%) | 25/133 (18.8%) |
| Median duration of “stabilisation”/time to progression | 1.7 months (range: 0.7 to 24.9 months) | NR | NR | NR | 5.5 months (range: 1.3 to 20.5 months)d |
| Disease free survival | NR | NR | NR | NR | NR |
| Health related quality of life | NR | NR | NR | NR | NR |
| N (%) discontinuations due to adverse events | NR | NR | NR | NR | 11/97 (11.6%)c |
| N(%) with ≥1 dose delay | NR | NR | NR | 18/77 (23.3%) | NR |
| N(%) with ≥1 dose reduction | NR | NR | NR | 12/77 (15.6%) | NR (31%) |
NR not reported
aUnless explicitly stated to be a reported range
bOne patient only achieved response/stable disease following further dose escalation to 800 mg/day
cFigure estimated from data reported in the paper
dUnit of measurements has been converted to months by dividing by 28 (for days), dividing by 4 (weeks), or multiplying by 12 (years)